Nisa Investment Advisors LLC Buys 1,300 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Nisa Investment Advisors LLC boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 115.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,430 shares of the company’s stock after acquiring an additional 1,300 shares during the period. Nisa Investment Advisors LLC’s holdings in Amphastar Pharmaceuticals were worth $150,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. BlackRock Inc. lifted its position in Amphastar Pharmaceuticals by 1.1% during the 3rd quarter. BlackRock Inc. now owns 7,147,813 shares of the company’s stock valued at $200,854,000 after acquiring an additional 75,616 shares during the period. Federated Hermes Inc. lifted its position in Amphastar Pharmaceuticals by 0.7% during the 1st quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company’s stock valued at $125,199,000 after acquiring an additional 23,095 shares during the period. Vanguard Group Inc. lifted its position in Amphastar Pharmaceuticals by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,606,162 shares of the company’s stock valued at $73,234,000 after acquiring an additional 45,385 shares during the period. Dimensional Fund Advisors LP lifted its position in Amphastar Pharmaceuticals by 2.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,917,571 shares of the company’s stock valued at $71,909,000 after acquiring an additional 51,027 shares during the period. Finally, State Street Corp lifted its position in Amphastar Pharmaceuticals by 16.6% during the 2nd quarter. State Street Corp now owns 1,540,846 shares of the company’s stock valued at $53,606,000 after acquiring an additional 218,895 shares during the period. 65.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AMPH shares. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. Finally, JPMorgan Chase & Co. began coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $66.00.

Insider Activity

In other news, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the completion of the transaction, the director now directly owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the sale, the director now directly owns 80,333 shares in the company, valued at $4,265,682.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The disclosure for this sale can be found here. Insiders sold 14,000 shares of company stock valued at $660,860 over the last three months. Insiders own 28.40% of the company’s stock.

Amphastar Pharmaceuticals Stock Up 3.5 %

Shares of Amphastar Pharmaceuticals stock opened at $40.01 on Friday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.70 and a current ratio of 2.17. The stock has a market capitalization of $1.96 billion, a PE ratio of 15.51, a price-to-earnings-growth ratio of 0.96 and a beta of 0.84. Amphastar Pharmaceuticals, Inc. has a 52-week low of $35.62 and a 52-week high of $67.66. The company has a 50-day simple moving average of $46.27 and a two-hundred day simple moving average of $51.14.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million for the quarter, compared to analysts’ expectations of $174.90 million. On average, analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.42 EPS for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.